CADRENAL THERAPEUTICS INC (CVKD) Fundamental Analysis & Valuation

NASDAQ:CVKD • US1276362076

Current stock price

6.35 USD
-0.32 (-4.8%)
At close:
6.25 USD
-0.1 (-1.57%)
After Hours:

This CVKD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CVKD Profitability Analysis

1.1 Basic Checks

  • In the past year CVKD has reported negative net income.
  • CVKD had a negative operating cash flow in the past year.
  • In the past 5 years CVKD always reported negative net income.
  • CVKD had a negative operating cash flow in each of the past 5 years.
CVKD Yearly Net Income VS EBIT VS OCF VS FCFCVKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 -2M -4M -6M -8M -10M

1.2 Ratios

  • CVKD has a worse Return On Assets (-305.95%) than 94.76% of its industry peers.
  • CVKD has a worse Return On Equity (-483.35%) than 85.34% of its industry peers.
Industry RankSector Rank
ROA -305.95%
ROE -483.35%
ROIC N/A
ROA(3y)-169.75%
ROA(5y)N/A
ROE(3y)-245.05%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CVKD Yearly ROA, ROE, ROICCVKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 0 200 -200 400 -400 -600 -800

1.3 Margins

  • CVKD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CVKD Yearly Profit, Operating, Gross MarginsCVKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CVKD Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, CVKD has more shares outstanding
  • CVKD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CVKD Yearly Shares OutstandingCVKD Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 2M 4M 6M 8M
CVKD Yearly Total Debt VS Total AssetsCVKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

  • CVKD has an Altman-Z score of -15.79. This is a bad value and indicates that CVKD is not financially healthy and even has some risk of bankruptcy.
  • CVKD's Altman-Z score of -15.79 is on the low side compared to the rest of the industry. CVKD is outperformed by 82.72% of its industry peers.
  • There is no outstanding debt for CVKD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.79
ROIC/WACCN/A
WACCN/A
CVKD Yearly LT Debt VS Equity VS FCFCVKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 5M -5M -10M

2.3 Liquidity

  • A Current Ratio of 2.72 indicates that CVKD has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.72, CVKD is in line with its industry, outperforming 45.03% of the companies in the same industry.
  • CVKD has a Quick Ratio of 2.72. This indicates that CVKD is financially healthy and has no problem in meeting its short term obligations.
  • CVKD has a Quick ratio of 2.72. This is comparable to the rest of the industry: CVKD outperforms 50.26% of its industry peers.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.72
CVKD Yearly Current Assets VS Current LiabilitesCVKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CVKD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 22.72% over the past year.
EPS 1Y (TTM)22.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CVKD will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.03% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.25%
EPS Next 2Y41.55%
EPS Next 3Y15.03%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CVKD Yearly Revenue VS EstimatesCVKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 20M 40M 60M 80M 100M
CVKD Yearly EPS VS EstimatesCVKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 0 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

0

4. CVKD Valuation Analysis

4.1 Price/Earnings Ratio

  • CVKD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CVKD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CVKD Price Earnings VS Forward Price EarningsCVKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CVKD Per share dataCVKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CVKD's earnings are expected to grow with 15.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.55%
EPS Next 3Y15.03%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CVKD Dividend Analysis

5.1 Amount

  • CVKD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CVKD Fundamentals: All Metrics, Ratios and Statistics

CADRENAL THERAPEUTICS INC

NASDAQ:CVKD (5/1/2026, 8:19:36 PM)

After market: 6.25 -0.1 (-1.57%)

6.35

-0.32 (-4.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength67.7
Industry Growth15.53
Earnings (Last)03-31
Earnings (Next)05-06
Inst Owners8.06%
Inst Owner Change0%
Ins Owners9.76%
Ins Owner Change-1.45%
Market Cap15.94M
Revenue(TTM)N/A
Net Income(TTM)-13.24M
Analysts82.86
Price Target28.22 (344.41%)
Short Float %2.2%
Short Ratio0.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.23%
Min EPS beat(2)-20.34%
Max EPS beat(2)15.87%
EPS beat(4)1
Avg EPS beat(4)-11.06%
Min EPS beat(4)-24.94%
Max EPS beat(4)15.87%
EPS beat(8)1
Avg EPS beat(8)-28.13%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-18.63%
PT rev (3m)-22.43%
EPS NQ rev (1m)-21.8%
EPS NQ rev (3m)-21.8%
EPS NY rev (1m)-79%
EPS NY rev (3m)-144.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.82
P/tB 5.82
EV/EBITDA N/A
EPS(TTM)-6.7
EYN/A
EPS(NY)-5.48
Fwd EYN/A
FCF(TTM)-5.02
FCFYN/A
OCF(TTM)-5.02
OCFYN/A
SpS0
BVpS1.09
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -305.95%
ROE -483.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-169.75%
ROA(5y)N/A
ROE(3y)-245.05%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.72
Quick Ratio 2.72
Altman-Z -15.79
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.81%
EPS Next Y18.25%
EPS Next 2Y41.55%
EPS Next 3Y15.03%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.28%
EBIT Next 3Y-42.58%
EBIT Next 5YN/A
FCF growth 1Y-71.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71.27%
OCF growth 3YN/A
OCF growth 5YN/A

CADRENAL THERAPEUTICS INC / CVKD Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CADRENAL THERAPEUTICS INC (CVKD) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CVKD.


What is the valuation status of CADRENAL THERAPEUTICS INC (CVKD) stock?

ChartMill assigns a valuation rating of 0 / 10 to CADRENAL THERAPEUTICS INC (CVKD). This can be considered as Overvalued.


What is the profitability of CVKD stock?

CADRENAL THERAPEUTICS INC (CVKD) has a profitability rating of 0 / 10.


What is the financial health of CADRENAL THERAPEUTICS INC (CVKD) stock?

The financial health rating of CADRENAL THERAPEUTICS INC (CVKD) is 6 / 10.


What is the expected EPS growth for CADRENAL THERAPEUTICS INC (CVKD) stock?

The Earnings per Share (EPS) of CADRENAL THERAPEUTICS INC (CVKD) is expected to grow by 18.25% in the next year.